Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Nkarta Inc. NKTX

Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of...


Recent & Breaking News (NDAQ:NKTX)

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire 5 days ago

Nkarta Announces Key Senior Leadership Team Appointments

GlobeNewswire July 25, 2022

Nkarta to Participate at Upcoming Investor Conference

GlobeNewswire May 31, 2022

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

GlobeNewswire May 16, 2022

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire May 12, 2022

Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

GlobeNewswire April 28, 2022

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire April 25, 2022

Nkarta Announces Proposed Public Offering of Common Stock

GlobeNewswire April 25, 2022

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

GlobeNewswire April 25, 2022

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates

GlobeNewswire April 22, 2022

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

GlobeNewswire April 8, 2022

Nkarta to Participate at Upcoming Investor Conference

GlobeNewswire April 8, 2022

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors

GlobeNewswire March 29, 2022

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

GlobeNewswire March 17, 2022

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting

GlobeNewswire March 8, 2022

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire February 10, 2022

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

GlobeNewswire December 16, 2021

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

GlobeNewswire December 13, 2021

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

GlobeNewswire November 12, 2021

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

GlobeNewswire November 10, 2021